Valeant Pharmaceuticals International Inc (VRX): Today's Featured Health Care Winner

Valeant Pharmaceuticals International ( VRX) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 1.1%. By the end of trading, Valeant Pharmaceuticals International rose $2.27 (2.5%) to $92.47 on average volume. Throughout the day, 1,727,273 shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 1,921,200 shares. The stock ranged in a price between $90.87-$92.50 after having opened the day at $91.26 as compared to the previous trading day's close of $90.20. Other companies within the Health Care sector that increased today were: Rexahn Pharmaceuticals ( RNN), up 16.8%, Alnylam Pharmaceuticals ( ALNY), up 15.8%, Rockwell Medical ( RMTI), up 15.7% and Bacterin International Holdings ( BONE), up 14.9%.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. Valeant Pharmaceuticals International has a market cap of $29.9 billion and is part of the drugs industry. Shares are up 50.9% year to date as of the close of trading on Wednesday. Currently there are 9 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and generally higher debt management risk.

On the negative front, Pingtan Marine Enterprise ( PME), down 69.2%, Mast Therapeutics ( MSTX), down 34.5%, Merrimack Pharmaceuticals ( MACK), down 28.0% and Inovio Pharmaceuticals ( INO), down 11.6%.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

Super Bowl of Earnings: Cramer's 'Mad Money' Recap (Friday 1/26/18)

Super Bowl of Earnings: Cramer's 'Mad Money' Recap (Friday 1/26/18)

Valeant CEO: Drugmaker Knee-Deep in 'Turnaround Effort of a Lifetime'

Valeant CEO: Drugmaker Knee-Deep in 'Turnaround Effort of a Lifetime'

5 Things We Learned About Activist Investing in 2017

5 Things We Learned About Activist Investing in 2017

Valeant Pharmaceuticals Stock Still a Dog?

Valeant Pharmaceuticals Stock Still a Dog?

No Two Stocks Are the Same: Cramer's 'Mad Money' Recap (Tuesday 12/12/17)

No Two Stocks Are the Same: Cramer's 'Mad Money' Recap (Tuesday 12/12/17)